Home
Sumitomo Dainippon Pharma Oncology

Sumitomo Dainippon Pharm... Market Share Analysis for June 2026

sumitomo pharma oncology is a global developer of novel cancer therapeutics. learn about our diverse and purposeful pipeline of targeted therapies.

Health > Biotechnology and Pharmaceuticals

Domainsdponcology.com

Year Founded2020

Employees201 - 500

Annual Revenue--

Sumitomo Dainippon Pharma Oncology

Sumitomo Dainippon Pharma Oncology (including company regionals)

sdponcology.com

See more website traffic and engagement information

Total visits to Sumitomo Dainippon Pharma Oncology's top domains

Understand Sumitomo Dainippon Pharma Oncology market share and potential market reach.

Total visits last 3 months

No Data to Display

Avg. visit duration in Sumitomo Dainippon Pharma Oncology's top domains

Analyze Sumitomo Dainippon Pharma Oncology engagement metrics.

Average visit duration last 3 months

No Data to Display

Avg. pageviews on Sumitomo Dainippon Pharma Oncology's top domains

See how Sumitomo Dainippon Pharma Oncology keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

No Data to Display

Sumitomo Dainippon Pharma Oncology top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by Sumitomo Dainippon Pharma Oncology

These are the website technologies, by industry, used by Sumitomo Dainippon Pharma Oncology top domains

Advertising (2)

DoubleClick

Widget (2)

reCAPTCHA

Audio Video Media (1)

YouTube

Business Solutions (1)

DocuSign

More Technologies

7

See all

News & Signals from Sumitomo Dainippon Pharma Oncology

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsSumitomo Dainippon Pharma Oncology, Inc. hired Jatin J. Shah as Executive Vice President, Chief Medical Officer and Global Head of Development on Feb 22nd '22.Sumitomo Dainippon Pharma Oncology, Inc., a clinical-stage pharmaceutical company focused on research and development for novel cancer therapeutics, today announced the appointment of Jatin J. Shah, M.D. as Executive Vice President, Chief Medical Officer and Global Head of Development.

NewsSumitomo Dainippon Pharma Oncology, Inc. launched Phase 3 WIZARD 201G study on Dec 15th '21.Sumitomo Dainippon Pharma Oncology, Inc., a clinical-stage biopharmaceutical company focused on research and development for novel cancer therapeutics, today announced that the Phase 3 WIZARD 201G study will terminate following its second interim analysis after determining there is a low probability of meeting the primary endpoint of overall survival at the final analysis.

NewsSumitomo Dainippon Pharma Oncology, Inc. launches CanStem303C study.Sumitomo Dainippon Pharma Oncology, Inc., a developer of novel cancer therapeutics, today announced that the CanStem303C study evaluating the efficacy and safety of investigational agent napabucasin when given in combination with FOLFIRI with or without bevacizumab in patients with previously treated metastatic colorectal cancer failed to reach the primary endpoints of overall survival (OS).